These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8625542)

  • 1. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data.
    Yap PL
    Clin Ther; 1996; 18 Suppl B():43-58. PubMed ID: 8930441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral transmission by blood products: a perspective of events covered by the recent tribunal of enquiry into the Irish Blood Transfusion Board.
    Yap PL
    Ir Med J; 1997; 90(3):84, 86, 88. PubMed ID: 9183082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins.
    Dodd RY
    Clin Exp Immunol; 1996 May; 104 Suppl 1():31-4. PubMed ID: 8625541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins].
    Antonelli A; Neri S; Gasperini L; Alberti B; Saracino A; Gambuzza C; Agostini S; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):55-61. PubMed ID: 1468200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
    Morgenthaler JJ; Omar A
    Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial.
    Piazza M; Sagliocca L; Tosone G; Guadagnino V; Stazi MA; Orlando R; Borgia G; Rosa D; Abrignani S; Palumbo F; Manzin A; Clementi M
    Arch Intern Med; 1997 Jul; 157(14):1537-44. PubMed ID: 9236555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmission of hepatitis C virus in allografted patients: use of viral genotyping as an epidemiological marker.
    Gangneux JP; Traineau R; Tuveri R; Ravera N; Bureau C; Gluckman E; Benbunan M; Loiseau P
    Bone Marrow Transplant; 1996 Dec; 18(6):1131-3. PubMed ID: 8971383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission.
    Berger A; Doerr HW; Scharrer I; Weber B
    J Med Virol; 1997 Sep; 53(1):25-30. PubMed ID: 9298728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
    Piszkiewicz D; Kingdon H; Lee ML; Hooper J
    Dev Biol Stand; 1987; 67():327-31. PubMed ID: 2440745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of needs for plasma for fractionation in Europe.
    Burckhardt JJ
    Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients.
    Shores NJ; Maida I; Soriano V; Núnez M
    J Hepatol; 2008 Sep; 49(3):323-8. PubMed ID: 18486266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of infection from plasma products: specific preventative strategies.
    Burnouf T; Radosevich M
    Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the hepatitis C virus.
    Houghton M
    Liver Int; 2009 Jan; 29 Suppl 1():82-8. PubMed ID: 19207970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.